ICAAC 2007: Chicago, Illinois; September 17-20, 2007

Key Links:

By Topic:


The Body PRO Covers:
The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
SEPTEMBER 17-20, 2007

Conference Research Highlights

Featuring in-depth analysis from our team of expert faculty:

Calvin J. Cohen, M.D., M.S. Eric Daar, M.D. Edwin DeJesus, M.D. Benjamin Young, M.D., Ph.D.

About This Conference

The Body PRO's coverage of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2007) includes a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on ICAAC 2007, please visit the conference's Web site.

Funding for coverage of this conference is provided, in part, by Abbott Laboratories, Boehringer Ingelheim and Tibotec Pharmaceuticals.

This coverage was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Here are some highlights of our collection of ICAAC 2007 interviews:
  Jay Lalezari, M.D., discusses the BOSS study, the first randomized study to examine the use of a needle-free device for the administration of enfuvirtide (T-20, Fuzeon).

(3MB, 10 min.)
Read interview

Ben Young, M.D., Ph.D.  Ben Young, M.D., Ph.D., reviews his presentation, which analyzes the impact of tenofovir (TDF, Viread) on the kidney function of people who already have kidney disease.

(2.2MB, 5.5 min.)
Read interview

Pablo Tebas, M.D.  Pablo Tebas, M.D., discusses why people who stop taking HIV meds are potentially at a greater risk for cardiovascular disease than if they remain on treatment.

(3.9MB, 7.5 min.)
Read interview

For additional podcasts and transcripts, click here.